Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket.
Yuan, J., Simpson, R.D., Zhao, W., Tice, C.M., Xu, Z., Cacatian, S., Jia, L., Flaherty, P.T., Guo, J., Ishchenko, A., Wu, Z., McKeever, B.M., Scott, B.B., Bukhtiyarov, Y., Berbaum, J., Panemangalore, R., Bentley, R., Doe, C.P., Harrison, R.K., McGeehan, G.M., Singh, S.B., Dillard, L.W., Baldwin, J.J., Claremon, D.A.(2011) Bioorg Med Chem Lett 21: 4836-4843
- PubMed: 21741239
- DOI: https://doi.org/10.1016/j.bmcl.2011.06.043
- Primary Citation of Related Structures:
3Q3T - PubMed Abstract:
Structure-based design led to the discovery of a novel class of renin inhibitors in which an unprecedented phenyl ring filling the S1 site is attached to the phenyl ring filling the S3 pocket. Optimization for several parameters including potency in the presence of human plasma, selectivity against CYP3A4 inhibition and improved rat oral bioavailability led to the identification of 8d which demonstrated antihypertensive efficacy in a transgenic rat model of human hypertension.
Organizational Affiliation:
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA. jyuan@vitaerx.com